Roche sticks with C4T, adding up to $1B for molecular glue partnership
BioSpace
Roche is jumping into degrader-antibody conjugates, a modality that in recent years has attracted investments from Merck KGaA and Bristol Myers Squibb.
pharminent
April 9, 2026 (Last updated: April 9, 2026)
BioSpace
Roche is jumping into degrader-antibody conjugates, a modality that in recent years has attracted investments from Merck KGaA and Bristol Myers Squibb.
